Initial trials on 1,077 British adults found that the vaccine induced strong antibody and T-cell responses, which may improve further after a booster jab, as reported by the Telegraph.

There were found to be no serious adverse events, and minor side effects could be controlled by paracetamol, two papers in The Lancet reported.